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INTRODUCTION
A major contributor to atherosclerotic plaque instability and rup-
ture is vascular smooth muscle cell (VSMC) apoptosis. Although 
VSMC apoptosis is rarely observed in normal blood vessels, in 
human unstable atherosclerotic plaques, increased apoptosis 
rates are detected.1 Apoptotic VSMCs are located in the protective 
fibrous cap2 and are associated with thinning and loss of fibrous cap 
integrity.3 Mouse models have provided direct evidence that VSMC 
apoptosis causes an increase in plaque instability.4–6 Apoptosis of 
other cell types, including macrophages, is also observed as lesions 
develop. Accordingly, reducing apoptosis, and in particular, VSMC 
apoptosis has been considered as a potential and novel therapeutic 
strategy to prevent atherosclerotic plaque rupture.
Cadherins are homophilic cell–cell adhesion molecules and 
are involved in prosurvival signaling in various cell types, includ-
ing VSMCs. Expression of cadherins is cell type specific, VSMCs 
express N-cadherin, and overexpression of N-cadherin signifi-
cantly increase VSMC survival.4,7 Soluble N-cadherin (SNC), which 
consists of the extracellular domain, acts as a mimetic to the full-
length molecule and also increases VSMC survival. Importantly, 
SNC was conjugated to the Fc domain to increase half-life in vivo 
and to ease purification for in vitro and in vivo studies (SNC-Fc).
We have previously shown that SNC-Fc activated the fibroblast 
growth factor receptor, resulting in activation of the prosurvival 
phosphoinositide 3 kinase/Akt/phospho-Bad pathway.8 SNC-Fc 
also reduced apoptosis in atherosclerotic plaques and increased 
features of atherosclerotic plaque stability in apolipoprotein 
E–deficient mice,8 suggesting that SNC-Fc may have therapeutic 
potential for retarding plaque instability.
A soluble molecule has obvious advantages therapeutically; 
however, at ~120 kDa, SNC-Fc is a rather large therapeutic mol-
ecule, therefore, we aimed to identify the active antiapoptotic 
site and evaluate whether a smaller molecule containing this 
site retained the antiapoptotic and plaque stabilizing proper-
ties. SNC consists of five extracellular (EC) domains: EC1–EC5. 
SNC has two binding domains: the homophilic N-cadherin bind-
ing domain (HAV/INPISGQ) in EC1 and the FGFR binding domain 
(INPDVGQ) in EC4.9Our previous work suggests that SNC-Fc can 
activate the FGFR, as well as phosphoinositide 3 kinase and Akt 
signaling.8 However, it was unclear whether (i) SNC-Fc could 
interact with the FGFR directly; (ii) the interaction of SNC-Fc with 
N-cadherin on the cell surface was required for FGFR activation; 
or (iii) the interaction with N-cadherin caused additional activa-
tion of phosphoinositide 3 kinase and Akt.10–12 To investigate this 
further, we have mutated the two binding sites to prevent the 
interaction with either N-cadherin or FGFR.
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Atherosclerotic plaque instability is precipitated by vascular smooth muscle cell apoptosis in the fibrous cap, weakening it and 
leading to plaque rupture. We previously showed that reducing smooth muscle cell apoptosis with soluble N-cadherin (SNC) 
increased features of plaque stability. We have now identified the active site of SNC and examined whether a truncated form 
containing this site retains the antiapoptotic effect. SNC was mutated to prevent interaction with N-cadherin or fibroblast growth 
factor receptor (FGFR). Interaction with FGFR in the extracellular (EC) 4 domain of SNC was essential for the antiapoptotic effect. 
Therefore, we made a truncated form consisting of the EC4 domain. EC4 significantly reduced smooth muscle cell, macrophage, 
and endothelial cell apoptosis in vitro by ~70%, similar to SNC. Elevation of plasma levels of EC4 in male apolipoprotein E–deficient 
mice with existing atherosclerosis significantly reduced apoptosis in brachiocephalic artery plaques by ~50%. EC4 reduced plaque 
size and the incidence of buried fibrous layers and the macrophage:smooth muscle cell ratio (surrogate markers of plaque instabil-
ity). Interaction of EC4 with FGFR induced potent antiapoptotic signaling in vitro and in vivo. EC4 modulates atherosclerosis in mice 
demonstrating its therapeutic potential for retarding plaque size and instability.
Molecular Therapy — Methods & Clinical Development (2014) 1, 14004; doi:10.1038/mtm.2014.4; published online 26 March 2014
Keywords: apoptosis; atherosclerosis; cell adhesion molecules; smooth muscle
1Bristol Heart Institute, Bristol Royal Infirmary, Bristol, UK Correspondence: SJ George (s.j.george@bristol.ac.uk)
EC4, a truncation of soluble N-cadherin, reduces vascular smooth 
muscle cell apoptosis and markers of atherosclerotic plaque 
instability
Cressida A Lyon1, Jason L Johnson1, Stephen White1, Graciela B Sala-Newby1 and Sarah J George1
ARTICle
2EC4 domain of N-cadherin promotes plaque stability
CA Lyon et al.
Molecular Therapy — Methods & Clinical Development (2014) 14004 © 2014 The American Society of Gene & Cell Therapy
In this study, we have characterized mutated versions of SNC-Fc 
to determine the active antiapoptotic site and subsequently trun-
cated the molecule accordingly. We have then investigated whether 
the truncated form, EC4-Fc, retains prosurvival effects both in vitro 
and in vivo and has the potential for repressing plaque instability.
ReSUlTS
Mutation and truncation of SNC
To determine which part of the SNC molecule was responsible for 
its antiapoptotic effect, we mutated the two active sites present 
in the molecule (Figure 1a). SNC can bind to N-cadherin via an 
interaction between an HAV binding motif in the first extracellular 
domain (EC1) and with INPISGQ in the EC1 domain of an adjacent 
molecule. To prevent this interaction, both of these motifs were 
mutated in SNC. SNC can also interact with the FGFR through 
INPDVGQ in the EC4 domain; therefore, this motif was mutated to 
prevent this interaction.
Interestingly, we found that when the N-cadherin binding sites 
were mutated (N-cad mut), this form of SNC-Fc still reduced VSMC 
apoptosis (Figure 1b). In contrast, when the FGFR binding site was 
mutated (FGFR mut), this form of SNC-Fc could no longer reduce 
Fas-L–induced VSMC apoptosis (Figure 1b). This suggested that 
the interaction of the FGFR with the EC4 domain of SNC-Fc was 
essential for the reduction in VSMC apoptosis. Therefore, we trun-
cated SNC-Fc (~120 kDa) to EC4-Fc (~50 kDa). Accordingly, EC4-Fc 
reduced VSMC apoptosis to an extent similar to that of the full 
SNC-Fc molecule (Figure 1c). However, when the FGFR binding site 
within EC4 was mutated (EC4 mut), EC4 no longer reduced apop-
tosis (Figure 1c).
EC4-Fc activated the FGFR and increased prosurvival phospho-Akt
We have previously shown that SNC-Fc reduced apoptosis by 
 activating the FGFR, resulting in activation of the downstream prosur-
vival phosphoinositide 3 kinase/Akt pathway.8 Immunocytochemistry 
for phospho-Akt (a prosurvival factor) demonstrated that EC4-Fc 
increased phospho-Akt to an extent similar to that of SNC-Fc (Figure 
1d), suggesting that it is functioning through the same pathway.
EC4-Fc reduced macrophage and endothelial apoptosis
Macrophage and endothelial cell apoptosis are also observed dur-
ing atherosclerotic plaque progression. EC4-Fc reduced apoptosis 
of blood monocyte–derived macrophages (Figure 2a) and human 
umbilical vein endothelial cells (Figure 2b) to an extent similar to 
that of SNC-Fc. As with VSMCs, this effect was ablated when the 
FGFR binding site was mutated (Figure 2a,b).
Figure 1  The effect of SNC-Fc mutation and truncation on vascular smooth muscle cell (VSMC) apoptosis. (a) Diagrammatic representation of 
the SNC-Fc molecule to show the locations of the fibroblast growth factor receptor (FGFR) and N-cadherin binding sites, the mutations to prevent 
binding, and truncation of SNC-Fc to EC4-Fc. (b,c) The percentage of apoptotic VSMCs (assessed by cleaved caspase-3 immunocytochemistry) 24 hours 
after induction of apoptosis with Fas-L and treatment with the purified proteins (mean ± SEM, n = 3, *P < 0.05 versus Fc, #P < 0.05 versus FGFR mutated, 
$P < 0.05 versus EC4 mutant). (d) EC4 activated Akt signaling to the same extent as SNC-Fc. Analysis of phospho-Akt immunocytochemistry following 
24-hour treatment with the purified proteins (mean ± SEM, n = 4, *P < 0.05 versus Fc, FGFR mutated and EC4 mutant). EC, extracellular; SNC, soluble 
N-cadherin.
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EC4-Fc reduced atherosclerotic plaque size and increased features 
of plaque stability
Plasma concentrations of EC4-Fc and SNC-Fc were increased in mice 
infected with RAd EC4-Fc or RAd SNC-Fc compared with that of RAd 
Fc–infected control mice. Importantly, there were no significant dif-
ferences in the plasma levels of low-density lipoprotein of the mice 
between the groups (Fc: 4.0 ± 1.3 mmol/l, SNC-Fc: 3.9 ± 1.2 mmol/l, 
EC4-Fc: 4.0 ± 1.4 mmol/l). Additionally, no adverse effects in the mice 
were observed.
Fluorescent immunohistochemistry for cleaved caspase-3 
showed that apoptosis within atherosclerotic plaques from the 
brachiocephalic artery was significantly reduced to a similar extent 
in the mice infected with RAd EC4-Fc and RAd SNC-Fc (Figure 3). 
Plaque size was measured at four points along the length of the bra-
chiocephalic artery, and the average was calculated. Interestingly, 
plaque size was significantly reduced in the mice infected with RAd 
EC4-Fc compared with that of Fc control mice (Figure 4a,b). No sig-
nificant effect on plaque size was observed in mice infected with 
RAd SNC-Fc.
The proportion of plaques exhibiting buried fibrous layers 
(a surrogate marker of plaque instability) were significantly 
reduced (>35%) in the mice infected with RAd EC4-Fc or RAd 
SNC-Fc compared with that of the Fc control mice (Figure 4a,c). 
These data suggest that EC4-Fc has an effect similar to that 
of SNC-Fc in vivo and are in line with our previous findings.8 
Additionally, we observed a significant increase (approximately 
threefold) in the ratio of VSMCs:macrophages, using specific cell 
type markers (Figure 5). This is further confirmation of a more 
stable plaque phenotype. As observed in our previous study, 
there were no differences in other plaque parameters measured 
(Table 1).
Figure 2 SNC-Fc and eC4 reduced apoptosis in macrophages and endothelial cells. Graphs show the percentage of apoptotic (a) macrophages and 
(b) endothelial cells as assessed by cleaved caspase-3 immunocytochemistry 24 hours after induction of apoptosis with Fas-L and treatment with the 
purified proteins (mean ± SEM, n = 3, *P < 0.05 versus Fc, fibroblast growth factor receptor (FGFR) mutated and EC4 mutant). EC, extracellular; HUVECs, 
human umbilical vein endothelial cells; SNC, soluble N-cadherin.
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Figure 3 eC4-Fc reduces apoptosis in vivo. (a) Quantification of the 
percentage of cleaved caspase-3–positive cells within the plaque 
(mean ± SEM, Fc n = 14, SNC n = 11, EC4 n = 13, *P < 0.05 versus Fc). (b) 
Representative cleaved caspase-3 immunohistochemistry (green) with 
4′,6-diamidino-2-phenylindole nuclear staining (blue) of brachiocephalic 
artery plaques. Bar = 50 µm. EC, extracellular; SNC, soluble N-cadherin.
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DISCUSSION
VSMC apoptosis is thought to be a major contributor to athero-
sclerotic plaque instability. Therefore, a therapeutic agent capable 
of reducing VSMC apoptosis in the fibrous cap of atherosclerotic 
plaques could be of great clinical benefit. We have previously shown 
that SNC-Fc significantly reduced apoptosis and increased features of 
atherosclerotic plaque stability.8 However, the therapeutic potential 
of SNC-Fc is limited due to the size of the molecule (~120 kDa). In the 
current study, we therefore aimed to identify the active antiapoptotic 
site within SNC and generate a smaller molecule, which may have 
greater therapeutic application. We have identified the active site of 
SNC-Fc as located within the EC4 domain and evaluated the effects 
of a truncated form of the molecule (~50 kDa and termed EC4-Fc) on 
apoptosis and atherosclerotic plaque progression. This study clearly 
identifies the potential for therapeutic strategies targeted at activat-
ing FGFR, in reducing the destabilization of atherosclerotic plaques.
SNC-Fc consists of five extracellular domains (EC1–EC5). Motifs 
within EC1 are responsible for interactions with N-cadherin, and 
another motif in EC4 is responsible for interactions with the FGFR. 
To investigate whether these sites are required for the previously 
observed antiapoptotic effect of SNC-Fc, we mutated the two sites 
independently of each other or in tandem to prevent their interac-
tions. Interestingly, the antiapoptotic effects of SNC-Fc were modu-
lated through the FGFR binding site within the EC4 domain. We 
have previously shown that SNC-Fc activates the FGFR.8 We there-
fore postulate that a direct interaction between SNC and FGFR is 
Figure 4 eC4-Fc reduces atherosclerotic plaque area and incidence of buried layers. (a) Representative elastin van Gieson stained plaques. Bar 
= 250 µm. (b) Analysis of plaque area, an average was taken from four measurements along the brachiocephalic artery. (c) Analysis of buried layers. 
“Unstable” plaques have at least one buried layer, “stable” plaques have none. Mean + SEM, Fc n = 15, SNC n = 12, EC4 n = 15, *P < 0.05 versus Fc). 
EC, extracellular; SNC, soluble N-cadherin.
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Figure 5 eC4-Fc increases the ratio of smooth muscle cells to macrophages (a marker of plaque stability). (a) Analysis of the ratio of vascular 
smooth muscle cells (VSMCs; actin) to macrophages (Griffonia simplicifolia lectin-1 (GSL); mean ± SEM, Fc n = 11, SNC-Fc n = 10, EC4-Fc n = 10, *P < 
0.05 versus Fc). (b) Representative images of GSL immunohistochemistry for macrophages and actin immunohistochemistry for VSMCs. Higher power 
images of the actin immunohistochemistry are shown in lower panels for clarity. Bar = 250 µm. EC, extracellular; SNC, soluble N-cadherin.
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essential for subsequent prosurvival signaling. In support of these 
observations, N-cadherin and FGFR have also been shown to inter-
act during neurite outgrowth, as reviewed in ref. 13. The smaller 
EC4-Fc reduced apoptosis to the same extent as that of SNC-Fc 
and activated the same prosurvival signaling pathway (Akt phos-
phorylation). EC4-Fc also reduced endothelial cell and macrophage 
apoptosis, to a level similar to that of SNC-Fc.
Moreover in vivo, elevated plasma levels of EC4-Fc reduced intra-
plaque frequencies of apoptosis, the number of buried layers, and 
plaque size when compared with the Fc control. In contrast and in 
accordance with our previous findings,8 elevated levels of SNC-Fc 
reduced apoptosis and the number of buried layers but had no sig-
nificant effect on plaque size. Also beneficially for plaque stability, 
both SNC-Fc and EC4-Fc significantly increased the smooth muscle 
cell:macrophage ratio. Taken together, these data demonstrate that 
both SNC and EC4, through interaction with the fibroblast growth fac-
tor receptor type 1, can prevent atherosclerotic plaque progression. 
Although it may appear counter-intuitive that EC4-Fc reduced macro-
phage apoptosis and the proportion of macrophages in the plaque, 
we suggest that the lower levels of apoptosis results in less secondary 
necrosis, inflammation, and proinflammatory cytokine production, 
leading to reduced influx of macrophages to the plaque.5,14–17
Our findings illustrate that in comparison to SNC, EC4 can act as a 
potent mimetic without any loss in functionality. Indeed, the in vivo 
study suggested that EC4 possesses greater activity as evidenced 
by the significant reduction in plaque area that was not observed in 
SNC-Fc animals. We postulate that the smaller molecular weight of 
EC4 may increase its permeability and therefore augment its access to 
intraplaque cells. Consequently in future studies, we will aim to design 
and test small peptides targeting the FGFR binding site. Indeed, a 
small peptide encoding the N-cadherin binding site in EC1, produc-
ing an HAV peptide which antagonises N-cadherin, is being trialed as 
a cancer chemotherapeutic,18 demonstrating that this approach has 
potential for clinical use.
In conclusion, this study demonstrates that site-specific trun-
cation of SNC (EC4) does not diminish its antiapoptotic activity. 
The ~50 kDa protein EC4-Fc reduced VSMC, endothelial cell, and 
macrophage apoptosis in vitro, and more importantly, reduced 
apoptosis, plaque size, and the number of buried layers within 
murine brachiocephalic artery atherosclerotic plaques, rendering 
them with an enhanced stable phenotype. Our findings, there-
fore, suggest that EC4-Fc, or possibly a smaller molecule, may have 
potential as a therapeutic in the treatment of atherosclerosis.
MATeRIAlS AND MeTHODS
VSMC culture
Human saphenous vein VSMCs at passages 4–8 were generated as 
described.4 Ethical permission for this study was gained from the local 
research ethics committee (NRES 07/H0107/61), and the study was approved 
by the University of Bristol and National Health Service Review Boards. Each 
experiment was carried out with VSMCs from at least three different seg-
ments of vein.
Purification and culture of mouse blood monocytes
Mouse peripheral blood monocytes were purified using Ficoll-Hypaque gra-
dient (Ficoll-Paque Plus; Amersham Biosciences, Little Chalfont, UK), followed 
by differential adherence and culture in 20 ng/ml of macrophage colony-
stimulating factor for 7–10 days to induce differentiation into macrophages.
SNC-Fc mutation and truncation
Two fragments containing the binding sites within EC1 and EC4 were sub-
cloned to facilitate polymerase chain reaction (PCR) mutagenesis. The first 
contained the HAV and INPISGQ motifs, which are required for interaction 
with N-cadherin,9 and was removed from SNC-Fc using BamHI and HindIII. 
The second contained the IDPVNGQ motif, which is required for interaction 
with FGFRs,9 and was removed from SNC-Fc using EcoRV and KpnI. These 
fragments were cloned into the pDRIVE cloning vector (Qiagen, Manchester, 
UK). PCR mutagenesis was used to mutate the binding sites of SNC. This pro-
duced the following mutations in the SNC sequence: HAV → HGV, INPISGQ 
→ INPASGQ, IDPVNGQ → IDAVNGQ, which were validated by sequencing. 
These mutated fragments were then shuttled back into SNC using the same 
restriction enzyme sites, to produce two plasmids: “N-cadherin mutated” 
and “FGFR mutated.” The native, mutated SNC constructs were then cloned 
into pCpG-free mcs (Invivogen, Toulouse, France) in which a myc-tagged FC 
domain (FCmyc) had already been cloned. The Fc domain, containing muta-
tions in the immunoglobulin G receptor and complement binding domains, 
was amplified by PCR from an IL-10-Fc fusion plasmid (generously provided 
by Terry Storm, Harvard University, Cambridge, MA). This chimeric molecule 
Table 1 The effect of EC4-Fc on atherosclerotic plaques in the mouse brachiocephalic artery
Fc (n = 14) SNC-Fc (n = 11) EC4-Fc (n = 13)
Cleaved caspase-3 (% total cells) 3.5 ± 0.5 2.1 ± 0.4* 1.4 ± 0.2*
VSMCs (% total plaque area) 0.8 ± 0.2 2.4 ± 0.6* 1.8 ± 0.4*
Fibrous cap coverage (% total plaque area) 12.2 ± 3.3 18.2 ± 4.4 20.3 ± 4.8
 Fibrous cap thickness (average) 65.03 ± 6.7 56.38 ± 8.8 67.8 ± 5.3
 Fibrous cap thickness (minimum) 10.1 ± 1.0 11.6 ± 2.7 10.6 ± 1.5
Macrophages (% total plaque area) 23.6.0 ± 3.8 21.6 ± 3.0 14.5 ± 2.1*
VSMC: macrophage ratio 0.038 ± 0.009 0.056 ± 0.009 0.122 ± 0.036*
Collagen (% of total plaque area)
 Polarized 5.69 ± 0.9 4.90 ± 1.0 5.07 ± 1.0
 Brightfield 50.15 ± 2.4 51.14 ± 3.1 52.66 ± 2.3
Lipid content (percentage of total plaque area) 51.09 ± 2.4 49.93 ± 3.1 49.35 ± 2.4
Necrotic core (percentage of total plaque area) 35.17 ± 4.0 54.38 ± 17.3 23.93 ± 5.3
Values are presented as mean ± SEM.
*Indicates significant difference from Fc, analysis of avriance, and Student–Newman–Keuls posttest .
SNC, soluble N-cadherin; VSMC, vascular smooth muscle cell.
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comprised of SNC and an antibody constant domain, which enables protein 
A binding, as well as extending plasma half-life19–21 and possibly increasing 
receptor–ligand interaction through its potential for dimerization. Such 
immunoadhesins have been used in vivo as potential therapeutic agents.22
The EC4 truncation was produced as follows. To facilitate secretion, the 
signal prepropeptide of SNC was cloned by PCR creating a BamHI site at the 
3′ end into FCmyc. This soluble Fc construct was used as a control (sFCmyc). 
The EC4 domain of SNC was excised by PCR introducing BamHI sites at each 
end. This product was cut with BamHI and ligated into sFCmyc to create 
sEC4-FCmyc and was validated by sequencing.
Adenovirus production
EcoRI fragments were prepared from sFCmyc or sEC4-FCmyc, which included 
the mouse cytomegalovirus enhancer, EF1α promoter, a short intron, the 
coding sequence, and a polyA site, and were cloned into pDC511 (Microbix, 
Ontario, Canada). Both were recombined with the adenovirus genomic plas-
mid by cotransfection into 293 cells. The resultant adenoviruses were termed 
RAd EC4-Fc and RAd Fc (control). RAd SNC-Fc was made as described.8
Purification of Fc, SNC-Fc, and mutated versions of SNC-Fc and 
EC4-Fc
Chinese hamster ovary cells were infected with 50 pfu/cell of RAd Fc, RAd 
SNC-Fc, or RAd EC4-Fc or subjected to AMAXA technology–mediated trans-
fection of plasmids for mutated versions of SNC-Fc. The conditioned media 
was collected at 66 and 138 hours after infection/transfection. The condi-
tioned media was pooled, and protein purification was achieved with pro-
tein A columns (Amersham Biosciences). The protein concentration was 
determined using the Bradford Protein assay (Sigma) and compared using 
western blotting.
Induction of VSMC, macrophage, and endothelial cell apoptosis
To enable the detection of apoptotic frequencies by immunocytochemistry, 
all cells were grown on glass coverslips. Human VSMC apoptosis was induced 
by culturing in serum-free media with 200 ng/ml of Fas-L for 24 hours. Blood-
derived macrophage apoptosis was induced by culture in serum-free media 
for 72 hours. Human umbilical vein endothelial cell apoptosis was induced by 
culture in serum-free media for 24 hours. Cells were supplemented with 20 
pmol/l of the respective purified proteins to assess their antiapoptotic effects.
Immunocytochemistry
Apoptosis was assessed by cleaved caspase-3 immunocytochemistry as 
described previously.7 Phosphorylated Akt was detected by immunocyto-
chemistry using rabbit anti-pAkt antibody (Cell Signaling, Danvers, MA), as 
described previously.8
In vivo mouse experiments
Homozygous C57BL/6, 129 male apolipoprotein E−/− mice (strain back-
ground 71% C57BL/6 and 29% 129) were bred within the Animal Unit of the 
University of Bristol. Housing, care, and all procedures were performed in 
accordance with the guidelines and regulations of the University of Bristol 
and the United Kingdom Home Office, and this study was approved by the 
University of Bristol Review Board. To induce the formation of complex ath-
erosclerotic lesions, 8-week-old male apolipoprotein E−/− mice were fed a 
high-fat rodent diet containing 21% (w/w) fat from lard supplemented with 
0.15% (w/w) cholesterol (Special Diets Services, Witham, UK) for a period of 8 
weeks. Mice were then given an i.v. dose of 8 × 1010 viral particles of an empty 
adenovirus (RAd66) as a predose 4 hours before administration of 2.25 × 108 
viral particles of RAd SNC-Fc (n = 12), RAd EC4-Fc (n = 14), or Fc (n = 15) 
as previously described.23 This protocol allows efficient hepatic transfection 
and expression, and subsequent elevated circulating levels of the respective 
transgene. Mice were then maintained on a high-fat diet for a further 28 days 
to determine effects on established lesions.
Quantification of plasma SNC-Fc/EC4 and lipoprotein levels
Plasma samples were taken at 6 and 28 days after RAd administration, and 
the levels of SNC-Fc and EC4 were analyzed using western blotting. For the 
SNC-Fc blots, plasmas were pretreated with protein A beads for 30 minutes 
at room temperature. Beads were centrifuged for 5 minutes at 13,000 rpm, 
the supernatant was removed, and the beads were resuspended in 30 µl of 
sodium dodecyl sulfate lysis buffer. These samples were subjected to west-
ern blotting as described previously.4 Blots were detected with a goat anti–
mouse horseradish peroxidase secondary antibody diluted 1:1,000 in milk 
overnight. To detect EC4, immunoprecipitation of c-myc using the ProFound 
c-myc tag IP/co-IP kit (Fisher Scientific, Loughborough, UK) was performed. 
Blots were detected with c-myc tag antibody (Cell Signaling) and a swine 
anti-rabbit secondary antibody (Dako, High Wycombe, UK).
Plasma lipid profiles were analyzed in terminal plasma samples as previ-
ously described.24
Immunohistochemistry
VSMCs, macrophages, and proliferating and apoptotic cells were identified 
by immunohistochemistry for α-smooth muscle cell actin, Griffonia sim-
plicifolia lectin-1, proliferating cell nuclear antigen, and cleaved caspase-3 
as described previously.8,23 Collagen was identified by PicroSirius red stain-
ing observed under polarized light.8,23 Positive staining was quantified using 
a computerized image analysis system (Image Pro Plus; Media Cybernetics, 
Rockville, MD) and expressed as the percentage of total plaque area.
Identification of buried fibrous layers
Serial sections stained for elastin and α-smooth muscle cell actin were exam-
ined for the presence of structures rich in elastin and VSMCs, and these were 
classed as buried fibrous layers, which we have previously identified as a sur-
rogate marker of previous plaque instability, as previously described.25
Statistical analysis
Values are expressed as mean ± SEM. Data were tested for normality. Then 
normally distributed data were analyzed by analysis of variance for multiple 
comparisons and the Student–Newman–Keuls posttest, and for experi-
ments with two groups, the paired t-test was utilized. Differences were con-
sidered significant when P < 0.05.
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